We thank Dr. Sebasti&#225;n Valenzuela and Dr. Micaela Ricca for their valuable veterinary assistance in our animal facility. This work was supported by &#34;Financiamiento Basal para Centros Cient&#237;ficos y Tecnol&#243;gicos de Excelencia de ANID&#34; Centro Ciencia &#38; Vida, FB210008 (to Fundaci&#243;n Ciencia &#38; Vida), and the Geroscience Center for Brain Health and Metabolism, FONDAP-15150012. This work was also funded by grants FONDECYT-1210013 (to R.P.) and FONDECYT-1150766 (to F.C.) from &#34;Agencia Nacional de Investigaci&#243;n y Desarrollo de Chile (ANID)&#34; and MJFF-10332.01 (to R.P.) and MJFF-17303 (to F.C.) from the Michael J Fox Foundation for Parkinson&#39;s Research.

All studies were carried out under the 8th edition of the Guide for the Care and Use of Laboratory Animals. Experimental protocols were approved by the IACUC at the Fundaci&#243;n Ciencia &#38; Vida (Science for Life Foundation), including those involving anesthesia, pain, distress, and euthanasia (Permit number P-035/2022).
1. The stereotaxic surgery
<ol>
	<li>Preparation for the surgery (approximately 1 h)
	<ol>
		<li>To maintain an aseptic environment, wear appropriate surgical clothes during the whole surgery, including shoe covers, a surgical mask, a sanitary barrier, gloves, and a surgical cap.</li>
		<li>Spray 70% ethanol on the mouse and all the surgical material to maintain an aseptic environment.</li>
		<li>To induce analgesia, inject the mouse with carprofen 5 mg/kg subcutaneously (s.c.) every 12 h21 starting 1 h before the surgery and continuing until 3 days after the surgery.</li>
		<li>To anesthetize the mouse, place the animal in an induction chamber. Open the isoflurane flow at a rate of 0.5% and then slowly increase it up to 5% over approximately 5 min until the mouse has lost its righting reflex22.</li>
		<li>Remove the animal from the induction chamber. Immediately transfer the animal to a non-rebreathing circuit with an appropriately sized nose cone. Maintain the mouse anesthesia with isoflurane 1% throughout the whole time of surgery.</li>
		<li>Confirm the mouse is entirely anesthetized by pinching its tail and paws. When the mouse does not react to pinching the tail and paws, it means the mouse is completely anesthetized.</li>
		<li>Shave the mouse&#39;s head using scissors. Clean the mouse&#39;s skin using a cotton swab with chlorhexidine 2% and remove all the hair.</li>
		<li>Fix the mouse&#39;s head in the stereotaxic frame.</li>
		<li>Place a corneal protectant in both mouse eyes using a cotton swab. To prevent stress induction in other rodents, avoid the presence of any other mouse in the surgery room23.</li>
	</ol>
	</li>
	<li>The surgery (approximately 30 min)
	<ol>
		<li>Clean the mouse&#39;s head with three rounds of 2% chlorhexidine followed by 70% ethanol. Expose the skull using surgical material and make a thin hole with a drill at the following coordinates: anteroposterior &#8722;2.8 mm, and mediolateral 1.4 mm with respect to the medial line.</li>
		<li>Put the needle of a 10 &#181;L syringe in the hole and move the needle inside the brain slowly until arriving at &#8722;7.2 mm dorsoventral with respect to the dura24.</li>
		<li>Leave the needle in the final position for 2 min to allow the tissue to settle a bit, and then inject 1 &#181;L of AAV5-CBA-h&#945;Syn (AAV-h&#945;Syn), AAV5-CBA-eGFP (AAV-GFP), or vehicle (PBS at pH 7.4; sham surgery) into the right substantia nigra at a rate of 0.2 &#181;L/30 s.</li>
		<li>Leave the needle in the same position for 5 min after the delivery of viral vectors and then withdraw it slowly.</li>
	</ol>
	</li>
	<li>Post-surgery (approximately 5 min)
	<ol>
		<li>Close the wound using a sterile silk-braided non-absorbable suture.</li>
		<li>Put the mouse in the home cage prewarmed by placing it over an electric heated mattress (25 &#176;C). 
		NOTE: The mouse must be maintained alone in the home cage until it is able to walk without difficulty and the wound has healed.</li>
	</ol>
	</li>
</ol>
2. Determination of motor performance using the beam test
<ol>
	<li>Training (approximately 15 min per mouse)
	<ol>
		<li>Twelve weeks after the stereotaxic surgery, assess the motor performance using a simplified version of the beam test described before25. For this purpose, use a horizontal beam of 25 cm in length and 3 cm in width. The beam surface must be covered with a metallic grid with squares of 1 cm and elevated 1 cm above the beam.</li>
		<li>Take a video of the mouse traversing the grid-surface beam from one end to the opposite end of the beam, where the home cage is located. Train the mouse for 2 days before the determination of motor performance.</li>
		<li>On the first day, train the mouse to walk through the beam five times without the grid.</li>
		<li>On the second day, train the mouse to walk through the beam in the presence of the grid five times.</li>
	</ol>
	</li>
	<li>The test (approximately 5 min per mouse)
	<ol>
		<li>On the third day, evaluate the motor performance. To do this, quantify the number of errors carried out by the left paws or by the right paws separately by watching the videos in slow-motion mode. 
		NOTE: An error is defined as when a paw does not correctly step on the grid and, therefore, becomes visible on the side of the grid or between the grid and the beam surface.</li>
	</ol>
	</li>
</ol>
3. Tissue processing
<ol>
	<li>Transcardial perfusion (approximately 15 min per mouse)
	<ol>
		<li>To anesthetize the mouse, inject a mixture of ketamine (80 mg/kg) and xylazine (10 mg/kg) intraperitoneally (i.p.) using a 1 mL syringe and 27 G needle26.</li>
		<li>Once the mouse is completely anesthetized (confirmed as in step 1.1.6.), open the thorax with surgical material and expose the heart.</li>
		<li>Then, insert a 21 G needle (make the tip flat using a drill) into the heart&#39;s left ventricle.</li>
		<li>By coupling the needle to a pipe, perfuse 50 mL of PBS (pH 7.4) at a rate of 9.5 mL/min using a peristaltic pump.</li>
	</ol>
	</li>
	<li>Fixing and cryoprotecting the brain (approximately 10 min per brain)
	<ol>
		<li>Remove the brain using scissors and tweezers, and then fix it by immersion in 5 mL of 4% paraformaldehyde in PBS (pH 7.4) at 4 &#176;C for 24 h.</li>
		<li>Afterward, put the fixed brain in 15 mL of 30% sucrose at 4 &#176;C for 48 h.</li>
		<li>Then, put the brain in 4 mL of cryoprotection solution (20% glycerine and 2% DMSO in PBS) and save the brain at &#8722;80 &#176;C or use it immediately in the next step.</li>
	</ol>
	</li>
	<li>Obtaining brain slices (approximately 20 min per brain). 
	NOTE: Ensure that the brain is placed in a cryostat in a proper position to make coronal cuts.
	<ol>
		<li>To obtain SN slices, cut the brain into 40 &#956;m thick sections starting at &#8722;2.92 mm and finishing at &#8722;3.64 mm24.</li>
		<li>Harvest each slice in a well (containing 1 mL of cryoprotection solution) of a 24-well plate following an anteroposterior order as described before25,27,28.</li>
		<li>To perform immunohistochemical (section 4.) and immunofluorescence analyses (section 5.) in the SN, choose six coronal SN sections taken at uniform intervals (120 &#181;m) that cover the entire rostrocaudal extent of the nucleus (720 &#956;m in total), as described before25,27,28.</li>
		<li>To obtain striatal slices, cut the brain into 40 &#956;m thick sections starting at +1.34 mm and finishing at &#8722;0.26 mm24.</li>
		<li>Harvest each slice in a 2 mL cryotube (containing 1 mL of cryoprotection solution) following an anteroposterior order.</li>
		<li>To perform immunohistochemical (section 4.) and immunofluorescence analyses (section 5.) in the striatum, choose five coronal striatal sections taken at uniform intervals (320 &#181;m) that cover the entire rostrocaudal extent of the nucleus (1600 &#956;m in total).</li>
	</ol>
	</li>
</ol>
4. Immunohistochemical analysis to quantify dopaminergic neurons and microgliosis (approximately 2 days)
<ol>
	<li>For immunohistochemical analysis of striatal or nigral slices, place the set of five (striatum) or six (SN) slices from the same brain in one well of a 24-well plate.</li>
	<li>Wash the sections 3x with 1 mL of PBS and then incubate with 0.5 mL of 0.03% H2O2 in methanol at room temperature and with agitation for 30 min to inactivate endogenous peroxidase activity.</li>
	<li>Wash the sections 3x with 1 mL of PBS and incubate with 0.5 mL of blocking solution (4% goat serum, 0.05% Triton X-100, and 4% BSA in PBS) at room temperature and with agitation for 40 min.</li>
	<li>Afterward, incubate with 0.5 mL of blocking solution containing the primary antibody (rabbit anti-tyrosine hydroxylase [TH] pAb diluted 1:1000 [see Table 1]; or rabbit anti-Iba1 antibody diluted 1:1000) at room temperature and with agitation overnight.</li>
	<li>Wash the sections 3x with 1 mL of PBS and incubate with 0.5 mL of blocking solution containing biotinylated goat anti-rabbit pAb (1:500, see Table 1) at room temperature and with agitation for 2 h.</li>
	<li>Then, wash the sections 3x with 1 mL of PBS and incubate with 0.5 mL of peroxidase-conjugated avidin (1:5000, see Table 1) in blocking solution at room temperature and with agitation for 90 min.</li>
	<li>Wash the sections 3x with 1 mL of PBS and incubate with 0.5 mL of substrate solution (0.05% diaminobenzidine in 0.03% H2O2/Trizma-HCl buffer at pH 7.6). Wear gloves and a lab coat for this step, as diaminobenzidine is a potential carcinogen.</li>
	<li>When the specific staining is evident (typically 30 sec for TH and 5 min for Iba1), take out the substrate solution and wash the sections 3x with 1 mL of PBS at room temperature and with agitation. Always carry out the immunostaining of slices of all the brains included in the same experiment simultaneously. 
	NOTE: The specific staining of TH is evident when TH immunostaining appears in the area of the SN, which displays a characteristic shape in the brain. The specific mark of Iba1 is determined when Iba1 immunostaining appears on control brain slices with typical microglial shapes, which are confirmed upon microscope observation. In this way, the exact time of substrate exposition for IHC analysis is determined for every single experiment.</li>
	<li>Mount the brain sections on glass slides using a solution of 0.2% gelatin in 0.05 M Tris (pH 7.6). Place each set of five (striatum) or six (SN) slices obtained from the same brain in rostrocaudal order on the same glass slide.</li>
	<li>Quantify the number of TH+ neurons in the SN.
	<ol>
		<li>To quantify TH+ neurons in the SN, acquire photos of the six slices at 20x magnification using a bright-field microscope, as described before25,27,28. Use the following adjust of color: color temperature 3200 K, cyan-red 40%, magenta-green 39%, yellow-blue 54%, gamma 0.5, contrast 37, brightness 13, saturation 5.</li>
		<li>Using the Image J software, select the perimeter of the SN pars compacta in the hemisphere analyzed. Avoid the selection of TH+ neurons from the ventral tegmental area (VTA).</li>
		<li>Afterward, ask the software to calculate the area selected (typically 0.04-0.07 mm2/hemisphere, depending on the rostrocaudal position). Then, using the multipoint tool, tag every single TH+ neuron with a dot.</li>
		<li>Using the point tool, ask the software to count the total number of dots. With the number of total dots (TH+ neurons) and the area of the SNpc, calculate the density of TH+ neurons/mm2.</li>
		<li>Repeat the same calculation in both hemispheres on the six SN slices and then calculate the mean of TH+ neurons/mm2 on the ipsilateral and the contralateral sides.</li>
	</ol>
	</li>
	<li>Quantify the number of activated microglia in the striatum
	<ol>
		<li>To quantify activated microglia in the striatum, acquire two photos in each hemisphere for all five striatal slices at 20x magnification using a bright-field microscope and the same settings indicated in step 4.10.1. Using the Image J software, in every single photo (displaying an area of 660 &#956;m x 877 &#956;m), tag with a dot every single cell expressing high Iba1 intensity and ameboid shape using the multipoint tool. Using the point tool, ask the software to count the total number of dots.</li>
		<li>With the number of total dots and the area of the photo, calculate the density of activated microglia (Iba1high cells/mm2) as performed before29.</li>
	</ol>
	</li>
</ol>

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Target antigen</td>
			<td>Coupled to</td>
			<td>Clonality</td>
			<td>Host specie</td>
			<td>Specie reactivity*</td>
			<td>Dilution**</td>
		</tr>
		<tr>
			<td>Tyrosine Hydroxylase</td>
			<td>N/A</td>
			<td>Polyclonal</td>
			<td>Rabbit</td>
			<td>Mouse, Rat, Human</td>
			<td>1/200 - 1/1000</td>
		</tr>
		<tr>
			<td>Iba1</td>
			<td>N/A</td>
			<td>Monoclonal</td>
			<td>Rabbit</td>
			<td>Mouse, Rat, Human</td>
			<td>1/1000</td>
		</tr>
		<tr>
			<td>alpha-Synuclein</td>
			<td>N/A</td>
			<td>Monoclonal</td>
			<td>Rabbit</td>
			<td>Human</td>
			<td>1/150</td>
		</tr>
		<tr>
			<td>CD4</td>
			<td>N/A</td>
			<td>Monoclonal</td>
			<td>Rat</td>
			<td>Mouse</td>
			<td>1/250</td>
		</tr>
		<tr>
			<td>IgG (H+L)</td>
			<td>Biotinilated</td>
			<td>Polyclonal</td>
			<td>Goat</td>
			<td>Rabbit</td>
			<td>1/500</td>
		</tr>
		<tr>
			<td>IgG (H+L)</td>
			<td>AlexaFluor 546</td>
			<td>Polyclonal</td>
			<td>Goat</td>
			<td>Rabbit</td>
			<td>1/500</td>
		</tr>
		<tr>
			<td>IgG (H+L)</td>
			<td>AlexaFluor 647</td>
			<td>Polyclonal</td>
			<td>Goat</td>
			<td>Rabbit</td>
			<td>1/500</td>
		</tr>
		<tr>
			<td>IgG (H+L)</td>
			<td>AlexaFluor 546</td>
			<td>Polyclonal</td>
			<td>Goat</td>
			<td>Rat</td>
			<td>1/500</td>
		</tr>
	</tbody>
</table>
Table 1: Antibody dilutions. N/A, not applicable. *, It is only specified if there are reactivities with mouse, rat, and human, irrespective of the reactivity with other species. **, A single dilution or a dilution range is specified.
5. Immunofluorescence analysis to evaluate T cell infiltration in the nigrostriatal pathway (approximately 2 days)
<ol>
	<li>For immunofluorescence analysis of h&#945;Syn or TH/GFP on striatal or nigral slices, put together the set of five (striatum) or six (SN) slices from the same brain in one well of a 24-well plate.
	<ol>
		<li>Wash the sections 3x with 1 mL of PBS and then incubate with 0.5 mL of blocking solution (0.3% Triton X-100, 0.05% tween20, and 5% BSA in PBS) at room temperature and with agitation for 40 min.</li>
		<li>Afterward, incubate with 0.5 mL of blocking solution containing the primary antibody (rabbit anti-TH pAb diluted 1:500; or rabbit anti-h&#945;Syn antibody diluted 1:150, see Table 1) at room temperature and with agitation overnight.</li>
	</ol>
	</li>
	<li>Wash the sections 3x with 1 mL of PBS and incubate with 0.5 mL of blocking solution containing AlexaFluor546-coupled anti-rabbit secondary antibody (1:500, see Table 1) and 4&#8242;,6-diamidino-2-phenylindole (DAPI; 1:1000) at room temperature and with agitation for 2 h. Then, wash the sections 3x with 1 mL of PBS.</li>
	<li>Mount the brain sections on glass slides as described above (step 4.9.). Images were acquired with an inverted fluorescence microscope coupled to a power supply unit.</li>
	<li>For immunofluorescence analysis of TH/CD4/GFP(Foxp3) on nigral slices, place the set of six (SN) slices from the same brain in one well of a 24-well plate. Wash the sections 3x with 1 mL of PBS and then incubate with 0.5 mL of blocking solution (0.5% Triton X-100, 0.5% fish skin gelatin in PBS) at room temperature and with agitation for 2 h.</li>
	<li>Incubate with 0.5 mL of blocking solution containing the primary antibodies rabbit anti-TH pAb (1:200, see Table 1) and rat anti-CD4 (1:250) at 4 &#176;C and with agitation overnight.</li>
	<li>Wash the sections 3x with 1 mL of PBS and incubate with 0.5 mL of blocking solution containing anti-rabbit coupled to AlexaFluor 647 (1:500, see Table 1) and anti-rat coupled to AlexaFluor 546 (1:500) at room temperature and with agitation for 2 h. Then, wash the sections 3x with 1 mL of PBS.</li>
	<li>Put each set of six (SN) slices obtained from the same brain in rostrocaudal order on the same glass slide and mount them using Fluoromount G. Acquire images using a Leica DMi8 microscope. Use the confocal microscope settings indicated in Table 2 to acquire images from immunofluorescence analysis.</li>
</ol>
<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>Chanel Name</td>
			<td>Cube</td>
			<td>Emission Wavelenght</td>
			<td>Lookup Table name</td>
			<td>Exposure time</td>
			<td>Gain</td>
			<td>Resolution XY</td>
			<td>Resolution Z</td>
		</tr>
		<tr>
			<td>Channel 1</td>
			<td>Y5</td>
			<td>700nm</td>
			<td>Grey</td>
			<td>1,011.727 ms</td>
			<td>high well capacity</td>
			<td>2.237 um</td>
			<td>24.444 um</td>
		</tr>
		<tr>
			<td>Channel 2</td>
			<td>GFP</td>
			<td>525nm</td>
			<td>Green</td>
			<td>326.851 ms</td>
			<td>high well capacity</td>
			<td>2.237 um</td>
			<td>24.444 um</td>
		</tr>
		<tr>
			<td>Channel 3</td>
			<td>TXR</td>
			<td>630nm</td>
			<td>Red</td>
			<td>406.344 ms</td>
			<td>high well capacity</td>
			<td>2.237 um</td>
			<td>24.444 um</td>
		</tr>
		<tr>
			<td>Channel 4</td>
			<td>Dapi</td>
			<td>460nm</td>
			<td>Blue</td>
			<td>91.501 ms</td>
			<td>high well capacity</td>
			<td>2.237 um</td>
			<td>24.444 um</td>
		</tr>
	</tbody>
</table>
Table 2: Confocal microscope settings used for the acquisition of images from immunofluorescence analysis.
6. Statistical analysis
<ol>
	<li>To compare data obtained from the ipsilateral and the contralateral sides, use a paired two-tailed Student&#39;s t-test.</li>
	<li>To compare data obtained from mice receiving AAV-h&#945;Syn and from mice receiving AAV-GFP or sham surgery, use an unpaired two-tailed Student&#39;s t-test. Consider significant differences when P values &#60; 0.05.</li>
</ol>

The authors declare that the research was conducted in the absence of any financial or non-financial competing interests.

The mouse model of neurodegeneration analyzed here might help study many critical aspects involved in the pathophysiology of Parkinson&#39;s disease, including the mechanisms involved in &#945;Syn pathology and microglial activation, the involvement of the peripheral immune system in the regulation of neuroinflammation, and the mechanisms of neurodegeneration. Among the mechanisms involved in &#945;Syn pathology are those subcellular mechanisms associated with mitochondrial, lysosomal, or proteasomal dysfunction in the presence of an excessive load of &#945;Syn in the dopaminergic neurons of the SN2. It is important to consider that, in addition to the h&#945;Syn expression induced by AAV-mediated transduction, the endogenous mouse &#945;Syn also contributes to the load of total &#945;Syn expression. Transgenic mice over-expressing mouse &#945;Syn develop similar synuclein pathology, neuropathology, and motor impairment to those mouse models based on the overexpression of h&#945;Syn32. Regarding microglial activation, the present mouse model might be used to study how different molecular and cellular players such as cytokines, neurotransmitters, astrocytes, neurons, the blood-brain barrier, and T cells might regulate the acquisition of pro-inflammatory or anti-inflammatory functional phenotypes8,10,11. This model also constitutes an important tool for studying the role of the peripheral immune system, including not only T cells but also macrophages, monocytes, and neutrophils, on the processes of neuroinflammation and neurodegeneration of nigral neurons11,33,34. Finally, this mouse model also represents a valuable system to study the cellular and molecular mechanisms of neurodegeneration in vivo, including those induced by internal cellular processes, such as oxidative stress, energy deficits, and damaged organelles 2, or those exerted by external players, such as neurotoxic factors produced by microglial cells, astrocytes, and cytotoxic T cells8,28,29,35.&#160;
A limitation of this mouse model is the study of how the pathological aggregation of &#945;Syn in extra-cerebral locations might constitute the initial stages in the development of Parkinson&#8217;s disease36. In this regard, there is growing evidence indicating that, before the neurodegeneration of nigral neurons and motor impairment, &#945;Syn pathology begins in the gut mucosa and the olfactory epithelium36 and, probably, the &#945;Syn-specific T-cell response as well12. Afterward, &#945;Syn aggregates would migrate through the vagus nerve to the brain stem, triggering the neuroinflammation and neurodegeneration of dopaminergic neurons12. Although the AAV-h&#945;Syn model recapitulates most aspects of Parkinson&#8217;s disease, there is no evident involvement of the pathological aggregation of &#945;Syn in extra-cerebral locations in this model. An alternative model involving h&#945;Syn pathology appropriate for studying these aspects of Parkinson&#8217;s disease might be transgenic mice overexpressing h&#945;Syn under the control of the Thy1 promoter, the Thy1-SNCA model37, in which disease development is dependent on the gut microbiota and involves an evident gastrointestinal impairment38.&#160;
Although it is helpful for the study of the diverse processes associated with the pathophysiology of Parkinson&#8217;s disease, the present mouse model involves critical steps that should be minutely checked, including the correct delivery of the viral vectors in the corresponding spatial coordinates, the selective expression of h&#945;Syn in neurons (which depends on the AAV serotype and the vector construct), and the proper AAV dose and timing before analyzing the Parkinsonian phenotype. The analysis of the proper delivery of the viral vectors in the SN is necessary, as the usage of the correct spatial coordinates of the SN might not be enough when the needle is not entirely straight, which is sometimes imperceptible to the human eye. Moreover, the diffusion of the AAV vectors depends on the AAV serotype39. For these reasons, it is necessary to perform periodical quality controls checking the correct delivery and diffusion of the injected AAV-GFP vectors following the observation of GFP in brain slices containing the area of the SN.
Regarding the selective expression of h&#945;Syn in neurons, in principle, the expression of h&#945;Syn could be engineered to be controlled by a promoter selective for neurons or, even more precise, selective for dopaminergic neurons, such as the use of the TH promoter in AAV vectors to induce the selective expression of genes in dopaminergic neurons40. However, this strategy does not work when what is sought is overexpression of the gene of interest. For this reason, in the present model, it is essential to use a strong promoter (a promoter inducing high expression of the downstream gene) and AAV serotypes with neuronal tropism. In this study, the CBA promoter was used as a strong promoter to induce the overexpression of h&#945;Syn, and the AAV5 serotype was used for the viral vector. This serotype has been used before to transduce mouse and rat neurons41,42. Here, the results demonstrated that, 12 weeks after the delivery of AAV5-GFP in the SN of mice, the green fluorescence was selectively present on the ipsilateral side of both the SN and striatum (Figure 1), indicating the efficient transduction of neurons of the nigrostriatal pathway.&#160;
Another critical aspect of this mouse model of Parkinson&#8217;s disease is the time point required to analyze a particular process after surgery. In this regard, this work shows a kinetic study of different processes involved in the pathology. Since key time points change with the dose of viral genomes given per mouse, the serotype of AAV used, or even with the batch of AAV used, a dose-response analysis of the amount of AAV-&#945;Syn required to induce a significant loss of TH+ neurons and motor impairment was first carried out. Previous studies have shown significant motor impairment and a loss of TH+ neurons of the nigrostriatal pathway after 12 weeks of AAV-&#945;Syn injections in mice at doses ranging from 6 x 108&#8211;3 x 1010 viral genomes per mouse16,17,30,31. Accordingly, the dose of AAV-h&#945;Syn used to induce the h&#945;Syn expression in the nigrostriatal pathway, the loss of TH+ neurons, and motor impairment in mice ranged from 1 x 108&#8211;1 x 1010 viral genomes per mouse. Moreover, to control that the loss of TH+ neurons and motor impairment were induced by the overexpression of h&#945;Syn in the SN and not by AAV infection of neurons of the SN, control groups were included in which AAV coding for a reporter gene (AAV-eGFP) was delivered unilaterally in the SN of mice and neurodegeneration and motor impairment were determined. The results showed that, 12 weeks after the stereotaxic surgery, 1 x 1010 viral genomes per mouse was a proper dose of AAV5-h&#945;Syn, as mice receiving this viral load displayed significant h&#945;Syn in the nigrostriatal pathway (Figure 2 and Figure 3), loss of TH+ neurons (Figure 4), and motor impairment (Figure 5). In contrast, lower doses of AAV5-h&#945;Syn (1 x 108 viral genomes per mouse and 1 x 109 viral genomes per mouse) were not strong enough to reach significant changes in all these parameters together (Figures 2&#8211;4). Of note, the administration of AAV-GFP at 1 x 1010 viral genomes per mouse induced a low (~20%), but significant degree of loss of TH+ neurons of nigral dopaminergic neurons (Figure 4A,B). This result agrees with previous observations using this model41 and is probably the consequence of a low level of neuroinflammation induced by the administration of AAV vectors in the SN. Nevertheless, the extent of loss of TH+ neurons was significantly higher in mice receiving AAV5-h&#945;Syn compared with those receiving the same dose of AAV-GFP (Figure 4C). Of note, the kinetics of h&#945;Syn expression not only depend on the efficiency of transduction but also on the extent of AAV diffusion39. Since AAV diffusion depends on the AAV serotype, the precise key time points in this animal model may vary when using another AAV serotype different from AAV5.
Afterward, a kinetic analysis was conducted using 1 x 1010 viral genomes per mouse to determine key time points in this mouse model. Since current evidence has shown some early symptoms that appear before motor impairment, which would allow the early diagnosis of Parkinson&#8217;s disease43,44, these experiments sought to find the time point at which h&#945;Syn expression was already evident but in the absence of motor impairment. The results show that the onset of h&#945;Syn expression in the SN was at 5 weeks after the stereotaxic delivery of AAV-h&#945;Syn (Figure 6). This time point constitutes an interesting temporal point to start administering therapies tailored to stop the neuroinflammatory and neurodegenerative processes. Other key time points determined here were the peak times for two critical events associated with the neuroinflammation process: the time at which microglia reach the maximal degree of activation and the time of maximal T-cell infiltration into the SN. The results showed a curve with a trend reaching two waves of maximal microglial activation, the first one at 10 weeks after the surgery and the second one at 15 weeks after the surgery (Figure 7). The kinetic analysis of T-cell infiltration showed the peak time of Treg infiltration into the SN at 11 weeks after the stereotaxic surgery (Figure 8). Surprisingly, no effector T cells (CD4+ Foxp3-) were detected infiltrating the SN during the time frame analyzed (weeks 8&#8211;13 after surgery). Altogether, these results suggest a proper frame of time to start administering therapies geared toward stopping the process of neuroinflammation and attenuating T-cell infiltration into the SN using this preclinical model, which ranges between week 5 after surgery (the onset of h&#945;Syn overexpression) and week 10 after surgery (the first wave of neuroinflammation and T-cell infiltration)&#160;(Figure 9).
<img alt="Figure 9" class="xfigimg" src="/files/ftp_upload/63313/63313fig09.jpg" /> 
Figure 9: Summary of the key time points found for this animal model. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig09large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>

After Alzheimer&#39;s disease, Parkinson&#39;s disease is the second most prevalent neurodegenerative disease worldwide. The primary neurons affected in Parkinson&#39;s disease are those of the nigrostriatal pathway, which produce dopamine and control voluntary movement. As a consequence, the most characteristic symptom associated with this disorder is motor impairment. This pathology also involves the deposition of protein aggregates in the brain, which are composed mainly of &#945;-synuclein (&#945;Syn)1, a cytosolic protein associated to presynaptic terminals. Evidence has shown that the generation of pathogenic inclusions of &#945;Syn is triggered by misfolding or by some post-translational modifications of this protein2.
Notably, a close relationship has been established between &#945;Syn pathology and the loss of dopaminergic neurons of the nigrostriatal pathway in human Parkinson&#39;s disease and animal models3,4. Understanding how &#945;Syn aggregates are generated and how they induce neuronal death represents a significant challenge in the field. A growing group of studies has shown that, by increasing oxidative stress, mitochondrial dysfunction is one of the leading causes for the generation of &#945;Syn aggregates2. Indeed, several genes associated with Parkinson&#39;s disease risk encode proteins involved in mitochondrial function, morphology, and dynamics5,6. In addition, lysosomal dysfunction, which results in the accumulation of dysfunctional mitochondria and misfolded &#945;Syn constitutes another major event promoting the generation of &#945;Syn aggregates7.
Emerging evidence has indicated that, once &#945;Syn aggregates are deposited in the brain, these pathogenic proteins stimulate toll-like receptors (TLRs) on the microglia, thus triggering microglial activation and an initial inflammatory environment in the substantia nigra (SN)8,9. Furthermore, the evidence indicates that &#945;Syn aggregates are captured and presented by antigen-presenting cells to T cells, inducing an adaptive immune response specific to &#945;Syn10,11. These &#945;Syn-specific T cells subsequently infiltrate the brain and are restimulated by activated microglia, thus promoting the secretion of neurotoxic factors that evoke neuronal death9,10. Interestingly, several lines of evidence have suggested that &#945;Syn aggregates are generated first in the enteric nervous system and then transported through the vagus nerve to the brain stem12.
Several animal models of Parkinson&#39;s disease have been used for many years, including those induced by the administration of neurotoxic substances (i.e., 6-hydroxydopamine, paraquat, rotenone, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and those involving genetic conditions (i.e., mutant &#945;-synuclein, mutant leucine-rich repeat kinase 2)13. Despite models involving neurotoxin-induced neurodegeneration replicating some aspects of Parkinson&#39;s disease, none of them recapitulate all the essential aspects of the disease or are not progressive13. On the other hand, although genetic mouse models involving the expression of mutant versions of leucine-rich repeat kinase 2, mutant versions of &#945;-synuclein, or the overexpression of human wild-type &#945;-synuclein result in motor impairment and, in some cases, also the development of synucleinopathy, they do not reproduce prominent neurodegeneration of the nigral dopaminergic neurons, which is an essential aspect of Parkinson&#39;s disease13,14. A third kind of animal model of neurodegeneration has managed to meet most of the essential aspects of Parkinson&#39;s disease, the stereotaxic delivery of adeno-associated viral vectors (AAVs) encoding the human &#945;-synuclein (AAV-h&#945;Syn)14,15. Importantly, AAVs allow the transduction of neurons with high efficacy and in the long term in the adult brain of mammals. Furthermore, the stereotaxic delivery of AAV-h&#945;Syn in the SN has been shown to reproduce many of the essential aspects of the disease, including &#945;Syn pathology, microglial activation, neurodegeneration, and motor impairment16,17,18,19,20. This study presents an analysis of how the dose of viral vector and the time after viral vector delivery affects the extent of h&#945;Syn expression, neurodegeneration, and neuroinflammation in the nigrostriatal pathway, as well as the degree of motor impairment in the mouse model of unilateral stereotaxic delivery of h&#945;Syn in the SN.

<table border="1" fo:keep-together.within-page="1" fo:keep-with-next.within-page="always">
	<tbody>
		<tr>
			<td>ANIMALS AND ANIMAL FOOD</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Foxp3-GFP C57BL/6 mice</td>
			<td>The Jackson Laboratory (Bar Harbor, ME)</td>
			<td>Stock No:&#160;023800</td>
			<td></td>
		</tr>
		<tr>
			<td>Laboratory Rodent Diet</td>
			<td>LabDiet</td>
			<td>Rodent Diet 5001</td>
			<td>Standard Rodent diet</td>
		</tr>
		<tr>
			<td>Wild-type C57BL/6 mice</td>
			<td>The Jackson Laboratory (Bar Harbor, ME)</td>
			<td>Stock No: 000664</td>
			<td></td>
		</tr>
		<tr>
			<td>VIRAL VECTORS</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>AAV5-CBA-&#945;Syn</td>
			<td>University of Iowa Viral Vector Core Facility</td>
			<td>N/A</td>
			<td>Stock concentration at 10E13 vg/mL</td>
		</tr>
		<tr>
			<td>AAV5-CBA-eGFP</td>
			<td>University of Iowa Viral Vector Core Facility</td>
			<td>N/A</td>
			<td>Stock concentration at 9.5 x 10E12 vg/mL</td>
		</tr>
		<tr>
			<td>ANESTHETICS AND ANALGESICS</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Isoflurane</td>
			<td>Baxter</td>
			<td>218082</td>
			<td>1% for stereotaxic surgery</td>
		</tr>
		<tr>
			<td>Ketamine</td>
			<td>Drag Pharma</td>
			<td>CHE30</td>
			<td>70 mg/Kg&#160; for stereotaxic surgery</td>
		</tr>
		<tr>
			<td>Sevoflurane</td>
			<td>Baxter</td>
			<td>VE2L9117</td>
			<td>For before transcardial perfusion</td>
		</tr>
		<tr>
			<td>Tramadol</td>
			<td>Drag Pharma</td>
			<td>DPH134</td>
			<td>30 mg/Kg every 24 h</td>
		</tr>
		<tr>
			<td>Xylazine</td>
			<td>Centrovet</td>
			<td>EHL40</td>
			<td>9 mg/kg for stereotaxic surgery</td>
		</tr>
		<tr>
			<td>EQUIPMENT</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Beam test</td>
			<td>Home made</td>
			<td>N/A</td>
			<td>horizontal beam 25 cm length and 3 cm width. The beam surface was covered by a metallic grid (1 cm2).</td>
		</tr>
		<tr>
			<td>Cryostate</td>
			<td>Leica</td>
			<td>CM1520</td>
			<td></td>
		</tr>
		<tr>
			<td>Digital camera</td>
			<td>Nikon</td>
			<td>S2800 Coolpix</td>
			<td>For recording the beam test performance</td>
		</tr>
		<tr>
			<td>Microscope</td>
			<td>Olympus</td>
			<td>BX51</td>
			<td>Used for IHC analysis (section 4.4)</td>
		</tr>
		<tr>
			<td>Microscope</td>
			<td>Olympus</td>
			<td>IX71</td>
			<td>Used for IF analysis (section 5.3)</td>
		</tr>
		<tr>
			<td>Microscope</td>
			<td>Leica</td>
			<td>DMI8</td>
			<td>Used for IF analysis (section 5.7)</td>
		</tr>
		<tr>
			<td>New Standard Stereotaxic, mouse</td>
			<td>Stoelting, Wood Dale, IL, USA</td>
			<td>51500</td>
			<td>stereotaxic frame for surgery</td>
		</tr>
		<tr>
			<td>Peristaltic Pump</td>
			<td>Masterflex</td>
			<td>C-flex L/S16</td>
			<td></td>
		</tr>
		<tr>
			<td>Power supply unit</td>
			<td>Olympus</td>
			<td>U-RFL-T</td>
			<td>Used for IF analysis (section 5.3)</td>
		</tr>
		<tr>
			<td>Surgical suture</td>
			<td>Sylkam&#174;, B Braun</td>
			<td>C0760171</td>
			<td></td>
		</tr>
		<tr>
			<td>Syringe 100 U</td>
			<td>BD</td>
			<td>324918</td>
			<td>For anesthesia before transcardial perfusion, 29G needle</td>
		</tr>
		<tr>
			<td>Syringe RN 5uL SYR W/O NEEDLE</td>
			<td>Hamilton</td>
			<td>HA-7641-01</td>
			<td>For viral vector innoculation</td>
		</tr>
		<tr>
			<td>BUFFERS AND REAGENTS</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Aviden, Peroxidase Conjugate</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>189728</td>
			<td></td>
		</tr>
		<tr>
			<td>Bovine Serum Albumin</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>9048-46-8</td>
			<td></td>
		</tr>
		<tr>
			<td>Cryotrotection buffer</td>
			<td>Home made</td>
			<td>N/A</td>
			<td>20% glycerine and 2% DMSO in PBS</td>
		</tr>
		<tr>
			<td>DAPI</td>
			<td>Abcam</td>
			<td>ab228549</td>
			<td></td>
		</tr>
		<tr>
			<td>Diaminobenzidine</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>D8001</td>
			<td></td>
		</tr>
		<tr>
			<td>Fluoromount -G T</td>
			<td>Electron Microscopy Science</td>
			<td>17984-25</td>
			<td></td>
		</tr>
		<tr>
			<td>Gelatin</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>104078</td>
			<td></td>
		</tr>
		<tr>
			<td>Normal goat serum</td>
			<td>Jackson ImmunoResearch Laboratory</td>
			<td>5000121</td>
			<td></td>
		</tr>
		<tr>
			<td>Paraformaldehyde</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>104005</td>
			<td></td>
		</tr>
		<tr>
			<td>PBS</td>
			<td>Home made</td>
			<td>N/A</td>
			<td>0.125 M, pH 7.4</td>
		</tr>
		<tr>
			<td>Peroxidase inactivating buffer</td>
			<td>Home made</td>
			<td>N/A</td>
			<td>0.03% H2O2 in methanol</td>
		</tr>
		<tr>
			<td>Triton X-100</td>
			<td>Sigma-Aldrich</td>
			<td>9036-19-5</td>
			<td></td>
		</tr>
		<tr>
			<td>Trizma Hydrochloride</td>
			<td>Merck, Darmstadt, Germany</td>
			<td>1185-53-1</td>
			<td></td>
		</tr>
		<tr>
			<td>Tween 20</td>
			<td>Sigma-Aldrich</td>
			<td>822184</td>
			<td></td>
		</tr>
		<tr>
			<td>ANTIBODIES</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Biotin-SP (long spacer) AffiniPure Goat Anti-Rabbit IgG (H+L)</td>
			<td>Jackson ImmunoResearch Laboratory</td>
			<td>111065003</td>
			<td></td>
		</tr>
		<tr>
			<td>Goat anti-Rabbit IgG (H+L)&#160; Alexa Fluor 546</td>
			<td>ThermoFisher Scientific</td>
			<td>A11010</td>
			<td></td>
		</tr>
		<tr>
			<td>Goat anti-Rabbit IgG (H+L)&#160; Alexa Fluor 647</td>
			<td>ThermoFisher Scientific</td>
			<td>A21244</td>
			<td></td>
		</tr>
		<tr>
			<td>Goat anti-Rat IgG (H+L)&#160; Alexa Fluor 546</td>
			<td>ThermoFisher Scientific</td>
			<td>A11081</td>
			<td></td>
		</tr>
		<tr>
			<td>Rabbit monoclonal anti-alpha-Synuclein</td>
			<td>Abcam</td>
			<td>ab138501</td>
			<td></td>
		</tr>
		<tr>
			<td>Rabbit monoclonal anti-Iba-1</td>
			<td>Abcam</td>
			<td>EPR16588</td>
			<td></td>
		</tr>
		<tr>
			<td>Rabbit polyclonal anti-Tyrosine Hydroxylase</td>
			<td>Millipore</td>
			<td>AB152</td>
			<td></td>
		</tr>
		<tr>
			<td>Rat monoclonal anti-CD4</td>
			<td>Biolegend</td>
			<td>100402</td>
			<td></td>
		</tr>
		<tr>
			<td>SOFTWARES</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>GraphPad</td>
			<td>Prism</td>
			<td>6.0</td>
			<td>Fos stats analysis</td>
		</tr>
		<tr>
			<td>ImageJ</td>
			<td>National Institute of Health</td>
			<td>N/A</td>
			<td>For image analysis</td>
		</tr>
		<tr>
			<td>LAS X</td>
			<td>Leica</td>
			<td>N/A</td>
			<td>For image capture with Leica microscope</td>
		</tr>
		<tr>
			<td>ProgRes Capture Pro</td>
			<td>Jenoptik</td>
			<td>N/A</td>
			<td>For image capture with Olympus microscope</td>
		</tr>
		<tr>
			<td>VLC media player</td>
			<td>VideoLAN Organization</td>
			<td>N/A</td>
			<td>For analysis of behavioural tests</td>
		</tr>
	</tbody>
</table>

analyzing the parkinson's disease mouse model induced by adeno-associated viral vectors encoding human &#945;-synuclein

Parkinson&#39;s disease is a neurodegenerative disorder that involves the death of the dopaminergic neurons of the nigrostriatal pathway and, consequently, the progressive loss of control of voluntary movements. This neurodegenerative process is triggered by the deposition of protein aggregates in the brain, which are mainly constituted of &#945;-synuclein. Several studies have indicated that neuroinflammation is required to develop the neurodegeneration associated with Parkinson&#39;s disease. Notably, the neuroinflammatory process involves microglial activation as well as the infiltration of peripheral T cells into the substantia nigra (SN). This work analyzes a mouse model of Parkinson&#39;s disease that recapitulates microglial activation, T-cell infiltration into the SN, the neurodegeneration of nigral dopaminergic neurons, and motor impairment. This mouse model of Parkinson&#39;s disease is induced by the stereotaxic delivery of adeno-associated viral vectors encoding the human wild-type &#945;-synuclein (AAV-h&#945;Syn) into the SN. The correct delivery of viral vectors into the SN was confirmed using control vectors encoding green fluorescent protein (GFP). Afterward, how the dose of AAV-h&#945;Syn administered in the SN affected the extent of h&#945;Syn expression, the loss of nigral dopaminergic neurons, and motor impairment were evaluated. Moreover, the dynamics of h&#945;Syn expression, microglial activation, and T-cell infiltration were determined throughout the time course of disease development. Thus, this study provides critical time points that may be useful for targeting synuclein pathology and neuroinflammation in this preclinical model of Parkinson&#39;s disease.

Validating the correct delivery of AAV vectors in the dopaminergic neurons of the nigrostriatal pathway 
To study the processes of neuroinflammation, neurodegeneration, and motor impairment promoted by synuclein pathology, a mouse model of Parkinson&#39;s disease induced by the unilateral stereotaxic delivery of AAV encoding h&#945;Syn in the SN16,17,30,31 was used (see the experimental design in Supplementary Figure 1). To validate the correct delivery of AAV vectors in the dopaminergic neurons of the nigrostriatal pathway, AAV encoding GFP (AAV-GFP) was injected in the SN, and 12 weeks later, GFP fluorescence and tyrosine hydroxylase (TH) immunoreactivity were analyzed in the SN and striatum by immunofluorescence. The GFP-associated fluorescence was observed exclusively on the ipsilateral side, and there was significant colocalization with TH immunoreactivity in both the SN and striatum, indicating the correct delivery of AAV vectors in the dopaminergic neurons of the nigrostriatal pathway (Figure 1).
<img alt="Figure 1" class="xfigimg" src="/files/ftp_upload/63313/63313fig01.jpg" /> 
Figure 1: Analysis of the delivery of AAV-GFP in the nigrostriatal pathway. Mice received AAV-GFP (1 x 1010 vg/mouse) and 12 weeks later were sacrificed, and TH was immunostained in (A) the SN (scale bars are 118 &#181;m) and (B) the striatum (scale bars are 100 &#181;m). TH- and GFP-associated fluorescence were analyzed by epifluorescence microscopy. Nuclei were stained with DAPI. Representative images of merged or single staining of TH (red), GFP (green), and DAPI (blue) are shown. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig01large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
Setting up the dose of viral vector administered to induce neurodegeneration and motor impairment in the mouse model of Parkinson&#39;s disease induced by AAV-h&#945;Syn 
To test the dose of AAV-h&#945;Syn required to induce a significant overexpression of h&#945;Syn that promotes neurodegeneration of the nigral dopaminergic neurons, different doses (1 x 108 viral genomes [vg]/mouse, 1 x 109 vg/mouse, or 1 x 1010 vg/mouse) of AAV-h&#945;Syn were injected, and 12 weeks later, h&#945;Syn immunoreactivity and the extent of TH immunoreactivity were evaluated in the nigrostriatal pathway. Although h&#945;Syn immunoreactivity was evident with all doses tested in the SN (Figure 2), only mice receiving 1 x 1010 vg/mouse presented evident h&#945;Syn immunoreactivity in the striatum (Figure 3). Moreover, mice receiving 1 x 1010 vg/mouse of AAV-h&#945;Syn displayed a significant loss of dopaminergic neurons in the SN (Figure 4A,B). Although mice receiving 1 x 1010 vg/mouse of AAV-GFP displayed a low degree (~20%) of neuronal loss (Figure 4A,B), mice receiving the same dose of AAV-h&#945;Syn presented a significantly higher degree of neurodegeneration of nigral dopaminergic neurons (Figure 4C). Accordingly, further experiments were performed using 1 x 1010 vg/mouse of AAV-h&#945;Syn. In addition, the extent of motor impairment was determined in mice receiving different doses of AAV-h&#945;Syn by using the beam test (Figure 5A), as described before25. A significant reduction in motor performance was detected exclusively with 1 x 1010 vg/mouse of AAV-h&#945;Syn in the beam test both when comparing the number of errors made by the right and the left pads (Figure 5B) and when comparing the total number of errors of mice receiving AAV-h&#945;Syn compared with mice receiving the control vector AAV-GFP (Figure 5C). Accordingly, further experiments were performed using 1 x 1010 vg/mouse of AAV-h&#945;Syn.
<img alt="Figure 2" class="xfigimg" src="/files/ftp_upload/63313/63313fig02.jpg" /> 
Figure 2: Analysis of human &#945;-synuclein expression in the SN of mice treated with different doses of AAV-h&#945;Syn. Mice received AAV-h&#945;Syn at (A) 1 x 1010 vg/mouse, (B) 1 x 109 vg/mouse, or (C) 1 x 108 vg/mouse and 12 weeks later were sacrificed, and the h&#945;Syn expression was analyzed by immunofluorescence in the SN using epifluorescence microscopy. Nuclei were stained with DAPI. Representative images of merged or single staining of h&#945;Syn (red) or DAPI (blue) are shown. Scale bars are 118 &#181;m. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig02large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 3" class="xfigimg" src="/files/ftp_upload/63313/63313fig03.jpg" /> 
Figure 3: Analysis of human &#945;-synuclein expression in the striatum of mice treated with different doses of AAV-h&#945;Syn. Mice received AAV-h&#945;Syn at (A) 1 x 1010 vg/mouse, (B) 1 x 109 vg/mouse, or (C) 1 x 108 vg/mouse) and 12 weeks later were sacrificed, and the h&#945;Syn expression was analyzed by immunofluorescence in the striatum using epifluorescence microscopy. Nuclei were stained with DAPI. Representative images of merged or single staining of h&#945;Syn (red) or DAPI (blue) are shown. Scale bars are 100 &#181;m. The insert on the upper-right corner of the merged images shows an area of interest in higher magnification. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig03large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 4" class="xfigimg" src="/files/ftp_upload/63313/63313fig04.jpg" /> 
Figure 4: Loss of dopaminergic neurons of the SN in mice treated with different doses of AAV-h&#945;Syn or control vector. Mice received AAV-h&#945;Syn (1 x 1010 vg/mouse, 1 x 109 vg/mouse, or 1 x 108 vg/mouse) or AAV-GFP (1 x 1010 vg/mouse) and 12 weeks later were sacrificed, and TH was analyzed in the SNpc by immunohistochemistry. (A) Representative images. Scale bars, 100 &#181;m. (B,C) The density of neurons was quantified as the number of TH+ neurons/mm2. Data represent mean &#177; SEM. n = 3&#8211;8 mice per group. (B) A comparison of ipsilateral with contralateral sides was performed using the two-tailed paired Student&#8217;s t-test. (C) A comparison of ipsilateral sides from mice receiving 1 x 1010 vg/mouse of AAV-h&#945;Syn or AAV-GFP was carried out. (B,C) Whereas white bars indicate the quantification of TH+ neurons on the ipsilateral side of mice receiving AAV-h&#945;Syn, green bars indicate the quantification of TH+ neurons on the ipsilateral side of mice receiving AAV-GFP. Grey bars indicate the quantification of TH+ neurons on the contralateral side of the corresponding group. Comparisons were performed by a two-tailed unpaired Student&#8217;s t-test. *p &#60; 0.05; **p &#60; 0.01. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig04large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 5" class="xfigimg" src="/files/ftp_upload/63313/63313fig05.jpg" /> 
Figure 5: Analysis of the motor performance in mice treated with different doses of AAV-h&#945;Syn. Mice received different doses (1 x 1010 vg/mouse, 1 x 109 vg/mouse, or 1 x 108 vg/mouse) of AAV-h&#945;Syn or AAV-GFP, and 12 weeks later, the motor performance was evaluated by the beam test. (A) Image of a mouse walking on the beam. (B) The number of errors carried out by left limbs (contralateral) versus right limbs (ipsilateral) was quantified in the groups of mice receiving AAV-h&#945;Syn. (C) The total number of errors was compared between different experimental groups receiving the same dose of AAV-h&#945;Syn or AAV-GFP. Data represent mean &#177; SEM. n = 3&#8211;5 mice per group. Comparisons were performed by (B) a paired two-tailed Student&#8217;s t-test or by (C) an unpaired two-tailed Student&#8217;s t-test. *p &#60; 0.05; **p &#60; 0.01. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig05large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
Setting up the kinetics of the Parkinson&#39;s disease model induced by AAV-&#945;Syn 
After determining the proper AAV-h&#945;Syn dose used to induce a significant level of neurodegeneration and motor impairment, experiments to define the onset of h&#945;Syn overexpression were conducted. For this purpose, mice were treated with 1 x 1010 vg/mouse of AAV-h&#945;Syn or sham surgery. The extent of h&#945;Syn expression was analyzed in the SN once per week during weeks 2-5 after the stereotaxic surgery (see the experimental design in Supplementary Figure 2). The results show that, despite h&#945;Syn expression being detected at low levels as early as 2 weeks after the surgery, h&#945;Syn clusters appeared at week 5 after the stereotaxic surgery (Figure 6).
<img alt="Figure 6" class="xfigimg" src="/files/ftp_upload/63313/63313fig06.jpg" /> 
Figure 6: Analysis of the time course of human &#945;-synuclein expression in the SN of mice treated with AAV-h&#945;Syn. Mice received AAV-h&#945;Syn (1 x 1010 vg/mouse) or just the sham stereotaxic surgery, and the expression of h&#945;Syn in the SN was analyzed (A) 2 weeks, (B) 3 weeks, (C) 4 weeks, or (D) 5 weeks later by immunofluorescence using epifluorescence microscopy. Nuclei were stained with DAPI. Representative images of merged or single staining of h&#945;Syn (red) or DAPI (blue) are shown. Scale bars, 100 &#181;m. The insert on the upper-right corner of the merged images shows an area of interest in higher magnification. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig06large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
Afterward, experiments were conducted to determine the suitable time points to analyze neuroinflammation and T-cell infiltration in the central nervous system (CNS) after the stereotaxic delivery of AAV-h&#945;Syn. To determine the peak of microglial activation after the treatment of mice with AAV-h&#945;Syn, the extent of cells expressing high levels of Iba1 in the striatum was evaluated once per week during weeks 2-15 after the stereotaxic surgery. The results show a significant increase in microglial activation of the ipsilateral side compared with the contralateral side of mice 15 weeks after the AAV-h&#945;Syn treatment (Figure 7). The number of Treg (CD4+ Foxp3+) cells infiltrated into the SNpc was also evaluated at different time points after the stereotaxic delivery of AAV-h&#945;Syn by immunofluorescence followed confocal microscopy observation. The results show that the peak of Treg infiltration into the SNpc was at 11 weeks after surgery, whereas the extent of Treg infiltrating this area of the brain was lower at week 8 or week 13 after surgery (Figure 8). No CD4+ T cells were detected infiltrating the striatum (data not shown). Altogether, these results indicate that, using 1 x 1010 vg/mouse of AAV-h&#945;Syn, the most suitable time point to analyze neuroinflammation is week 15 after the stereotaxic surgery, while a proper time point to analyze T-cell infiltration into the CNS seems to be week 11 after AAV-h&#945;Syn treatment.
<img alt="Figure 7" class="xfigimg" src="/files/ftp_upload/63313/63313fig07.jpg" /> 
Figure 7: Analysis of the time course of microglial activation in mice inoculated with AAV-h&#945;Syn. Mice received AAV-h&#945;Syn (1 x 1010 vg/mouse), and microglial activation was evaluated by immunohistochemical analysis of Iba1 in the striatum at different time points after the surgery. (A) Representative overview images of immunohistochemical analysis of Iba1 from mice sacrificed 5 weeks, 10 weeks, or 15 weeks after inoculation with AAV-h&#945;Syn are shown. Scale bars, 110 &#181;m. (B) The density of activated microglia was quantified as the number of cells expressing high levels of Iba1 and ameboid shape per area. Data represent mean &#177; SEM. n = 3 mice per group. A two-tailed paired Student&#8217;s t-test was used to determine statistical differences between ipsilateral and contralateral Iba1 in each group. *p &#60; 0.05. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig07large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
<img alt="Figure 8" class="xfigimg" src="/files/ftp_upload/63313/63313fig08.jpg" /> 
Figure 8: Analysis of the time course of CD4+ T-cell infiltration into the SN of mice inoculated with AAV-h&#945;Syn. Foxp3gfp reporter mice received AAV-h&#945;Syn (1 x 1010 vg/mouse). The presence of CD4+ T-cells expressing Foxp3 and the presence of TH+ neurons were analyzed at different time points (week 8, week 11, and week 13 after the surgery) in the SN by immunofluorescence. (A) Representative images for single immunostaining or the merge are shown. Scale bars, 100 &#181;m. (B) The number of CD4+ Foxp3+ T cells per area in the SN was quantified. Data represent mean &#177; SEM from 3 mice per group. *p&#60;0.05, ipsilateral versus contralateral CD4+ Foxp3+ T cells by two-tailed Student&#8217;s t-test. <a href="https://www.jove.com/files/ftp_upload/63313/63313fig08large.jpg" target="_blank">Please click here to view a larger version of this figure.</a>
Supplementary Figure 1: Experimental design for evaluating the effect of different doses of AAV vectors on synuclein pathology, neurodegeneration, and motor impairment. Wild-type male C57BL/6 mice were anesthetized and received stereotaxic inoculation of different doses (1 x 1010 vg/mouse, 1 x 109 vg/mouse, or 1 x 108 vg/mouse) of AAV encoding human &#945;-synuclein (AAV-h&#945;Syn) or eGFP (AAV-GFP) under the control of the CBA promoter into the right substantia nigra (SN). After 12 weeks, the expression of GFP and h&#945;Syn in the SN and striatum (Str) were evaluated by immunofluorescence (IF), tyrosine hydroxylase positive (TH+) cells were quantified by immunohistochemistry (IHC) in the SN, and motor performance was evaluated by the beam test. The number of mice in each experimental group is indicated in parenthesis. * indicates groups where one mouse died before the analyses. Each analysis indicates in parenthesis the number of the figure from the body of the paper where the corresponding results are shown. <a href="https://www.jove.com/files/ftp_upload/63313/Supplementary Figure 1.zip" target="_blank">Please click here to download this File.</a>
Supplementary Figure 2: Experimental design for determining the kinetics of T-cell infiltration, neuroinflammation, and h&#945;Syn expression. Foxp3gfp reporter mice were anesthetized and received stereotaxic inoculation of AAV (1 x 1010 vg/mouse) encoding human &#945;-synuclein (AAV-h&#945;Syn) under the control of the CBA promoter into the right substantia nigra (SN) or sham surgery (PBS). Mice were sacrificed at different time points, and the expression of h&#945;Syn in the SN and striatum was evaluated by immunofluorescence (IF), GFP (Foxp3), CD4, and tyrosine hydroxylase positive (TH+) cells were quantified by IF in the SN, and Iba1 expression was analyzed by immunohistochemistry (IHC) in the striatum (Str). The number of mice in each experimental group is indicated. The range of time points included in each analysis is indicated. Each analysis indicates in parenthesis the number of the figure from the body of the paper where the corresponding results are shown. <a href="https://www.jove.com/files/ftp_upload/63313/Supplementary Figure 2.zip" target="_blank">Please click here to download this File.</a>

Watch this Scientific Journal Video about Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human ÃŽÂ±-Synuclein at JoVE.com

Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human &#945;-Synuclein

This work analyzes the vector dose and exposure time required to induce neuroinflammation, neurodegeneration, and motor impairment in this preclinical model of Parkinson&#39;s disease. These vectors encoding the human &#945;-synuclein are delivered into the substantia nigra&#160;to recapitulate the synuclein pathology associated with Parkinson&#39;s disease.

Parkinson&#39;s disease is a neurodegenerative disorder that involves the death of the dopaminergic neurons of the nigrostriatal pathway and, ...

analyzing-parkinson-s-disease-mouse-model-induced-adeno-associated

Research

JoVE Journal

Neuroscience

5.7K Views.  Fundación Ciencia & Vida. This work analyzes the vector dose and exposure time required to induce neuroinflammation, neurodegeneration, and motor impairment in this preclinical model of Parkinson's disease. These vectors encoding the human α-synuclein are delivered into the substantia nigra to recapitulate the synuclein pathology associated with Parkinson's disease.

Video: Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein

Intracranial Injection of Adeno-associated Viral Vectors

Intracranial injection of viral vectors engineered to express a fluorescent protein is a versatile labeling technique for visualization of specific subsets of cells in different brain regions both in vivo and in brain sections. Unlike the injection of fluorescent dyes, viral labeling offers targeting of individual cell types and is less expensive and time consuming than establishing transgenic mouse lines. In this technique, an adeno-associated viral (AAV) vector is injected intracranially using stereotaxic coordinates, a micropipette and an automated pump for precise delivery of AAV to the desired area with minimal damage to the surrounding tissue. Injection parameters can be tailored to individual experiments by adjusting the animal age at injection, injection location, volume of injection, rate of injection, AAV serotype and the promoter driving gene expression. Depending on the conditions chosen, virally-induced transgene expression can allow visualization of groups of cells, individual cells or fine cellular processes, down to the level of dendritic spines. The experiment shown here depicts an injection of double-stranded AAV expressing green fluorescent protein for the labeling of neurons and glia in the mouse primary visual cortex.

Here we present the intracranial injection of AAV vectors for fluorescent labeling of neurons and glia in the visual cortex.

Intracranial injection of viral vectors engineered to express a fluorescent protein is a versatile labeling technique for visualization of specific ...

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Alzheimer's disease (AD) is the most common neurodegenerative disorder leading to dementia. Neuritic plaque formation is one of the pathological hallmarks of Alzheimer's disease. The central component of neuritic plaques is a small filamentous protein called amyloid &beta; protein (A&beta;)1, which is derived from sequential proteolytic cleavage of the beta-amyloid precursor protein (APP) by &beta;-secretase and &gamma;-secretase. The amyloid hypothesis entails that A&gamma;-containing plaques as the underlying toxic mechanism in AD pathology2. The postmortem analysis of the presence of neuritic plaque confirms the diagnosis of AD. To further our understanding of A&gamma; neurobiology in AD pathogenesis, various mouse strains expressing AD-related mutations in the human APP genes were generated. Depending on the severity of the disease, these mice will develop neuritic plaques at different ages. These mice serve as invaluable tools for studying the pathogenesis and drug development that could affect the APP processing pathway and neuritic plaque formation. In this protocol, we employ an immunohistochemical method for specific detection of neuritic plaques in AD model mice. We will specifically discuss the preparation from extracting the half brain, paraformaldehyde fixation, cryosectioning, and two methods to detect neurotic plaques in AD transgenic mice: immunohistochemical detection using the ABC and DAB method and fluorescent detection using thiofalvin S staining method.

Detection of Neuritic Plaques in Alzheimer&#039;s Disease Mouse Model

One of the pathological characteristics of AD is the formation of Amyloid &#x03B2; protein positive neuritic plaques. In this protocol we describe two methods to detect neuritic plaques in transgenic AD model mice: immunohistochemical detection using the ABC and DAB method and fluorescent detection using thioflavin S staining method.

Alzheimer's disease (AD) is the most common neurodegenerative disorder leading to dementia. Neuritic plaque formation is one of the pathological hallmarks ...

Methods to Characterize Spontaneous and Startle-induced Locomotion in a Rotenone-induced Parkinson's Disease Model of Drosophila

Parkinson&#8217;s disease is a neurodegenerative disorder that results from the degeneration of dopaminergic neurons in the central nervous system, primarily in the substantia nigra. The disease causes motor deficiencies, which present as rigidity, tremors and dementia in humans. Rotenone is an insecticide that causes oxidative damage by inhibiting the function of the electron transport chain in mitochondria. It is also used to model Parkinson&#8217;s disease in the Drosophila. Flies have an inherent negative geotactic response, which compels them to climb upwards upon being startled. It has been established that rotenone causes early mortality and locomotion defects that disrupt the flies&#8217; ability to climb after they have been tapped downwards. However, the effect of rotenone on spontaneous movement is not well documented. This study outlines two sensitive, reproducible, and high throughput assays to characterize rotenone-induced deficiencies in short-term startle-induced locomotion and long-term spontaneous locomotion in Drosophila. These assays can be conveniently adapted to characterize other Drosophila models of locomotion defects and efficacy of therapeutic agents.

Methods to Characterize Spontaneous and Startle-induced Locomotion in a Rotenone-induced Parkinson&#039;s Disease Model of Drosophila

Parkinson&#8217;s disease is a neurodegenerative disorder that results from the degeneration of dopaminergic neurons in the central nervous system, causing locomotion defects. Rotenone models Parkinson&#8217;s disease in Drosophila. This paper outlines two assays that characterize both spontaneous and startle-induced locomotion deficiencies caused by rotenone.

Parkinson&#8217;s disease is a neurodegenerative disorder that results from the degeneration of dopaminergic neurons in the central nervous system, ...

Intracerebroventricular Viral Injection of the Neonatal Mouse Brain for Persistent and Widespread Neuronal Transduction

With the pace of scientific advancement accelerating rapidly, new methods are needed for experimental neuroscience to quickly and easily manipulate gene expression in the mouse brain. Here we describe a technique first introduced by Passini and Wolfe for direct intracranial delivery of virally-encoded transgenes into the neonatal mouse brain. In its most basic form, the procedure requires only an ice bucket and a microliter syringe. However, the protocol can also be adapted for use with stereotaxic frames to improve consistency for researchers new to the technique. The method relies on the ability of adeno-associated virus (AAV) to move freely from the cerebral ventricles into the brain parenchyma while the ependymal lining is still immature during the first 12-24 hr after birth. Intraventricular injection of AAV at this age results in widespread transduction of neurons throughout the brain. Expression begins within days of injection and persists for the lifetime of the animal. Viral titer can be adjusted to control the density of transduced neurons, while co-expression of a fluorescent protein provides a vital label of transduced cells. With the rising availability of viral core facilities to provide both off-the-shelf, pre-packaged reagents and custom viral preparation, this approach offers a timely method for manipulating gene expression in the mouse brain that is fast, easy, and far less expensive than traditional germline engineering.

Here we demonstrate a technique for widespread neuronal transduction by intraventricular injection of adeno-associated virus into the neonatal mouse brain. This method provides a rapid and easy way to attain lifelong expression of virally-delivered transgenes.

With the pace of scientific advancement accelerating rapidly, new methods are needed for experimental neuroscience to quickly and easily manipulate gene ...

Production, Purification, and Quality Control for Adeno-associated Virus-based Vectors

Gene delivery tools based on adeno-associated viruses (AAVs) are a popular choice for the delivery of transgenes to the central nervous system (CNS), including gene therapy applications. AAV vectors are non-replicating, able to infect both dividing and non-dividing cells&#160;and provide long-term transgene expression. Importantly, some serotypes, such as the newly described PHP.B, can cross the blood-brain-barrier (BBB) in animal models, following systemic delivery. AAV vectors can be efficiently produced in the laboratory. However, robust and reproducible protocols are required to obtain AAV vectors with sufficient purity levels and titer values high enough for in vivo applications. This protocol describes an efficient and reproducible strategy for AAV vector production, based on an iodixanol gradient purification strategy. The iodixanol purification method is suitable for obtaining batches of high-titer AAV vectors of high purity, when compared to other purification methods. Furthermore, the protocol is generally faster than other methods currently described. In addition, a quantitative polymerase chain reaction (qPCR)-based strategy is described for a fast and accurate determination of the vector titer, as well as a silver staining method to determine the purity of the vector batch. Finally, representative results of gene delivery to the CNS, following systemic administration of AAV-PHP.B, are presented. Such results should be possible in all labs using the protocols described in this article.

Here, we describe an efficient and reproducible strategy to produce, titer, and quality-control batches of adeno-associated virus vectors. It allows the user to obtain a vector preparation with high-titer&#160;(&#8805;1 x 1013 vector genomes/mL) and a high purity, ready for in vitro or in vivo use.

Gene delivery tools based on adeno-associated viruses (AAVs) are a popular choice for the delivery of transgenes to the central nervous system (CNS), ...

Convection Enhanced Delivery of Optogenetic Adeno-associated Viral Vector to the Cortex of Rhesus Macaque Under Guidance of Online MRI Images

In non-human primate (NHP) optogenetics, infecting large cortical areas with viral vectors is often a difficult and time-consuming task. Here, we demonstrate the use of magnetic resonance (MR)-guided convection enhanced delivery (CED) of optogenetic viral vectors into primary somatosensory (S1) and motor (M1) cortices of macaques to obtain efficient, widespread cortical expression of light-sensitive ion channels. Adeno-associated viral (AAV) vectors encoding the red-shifted opsin C1V1 fused to yellow fluorescent protein (EYFP) were injected into the cortex of rhesus macaques under MR-guided CED. Three months post-infusion, epifluorescent imaging confirmed large regions of optogenetic expression (&#62;130 mm2) in M1 and S1 in two macaques. Furthermore, we were able to record reliable light-evoked electrophysiology responses from the expressing areas using micro-electrocorticographic arrays. Later histological analysis and immunostaining against the reporter revealed widespread and dense optogenetic expression in M1 and S1 corresponding to the distribution indicated by epifluorescent imaging. This technique enables us to obtain expression across large areas of the cortex within a shorter period of time with minimal damage compared to the traditional techniques and can be an optimal approach for optogenetic viral delivery in large animals such as NHPs. This approach demonstrates great potential for network-level manipulation of neural circuits with cell-type specificity in animal models evolutionarily close to humans.&#160;

Here, we demonstrate magnetic resonance (MR)-guided convection enhanced delivery (CED) of viral vectors into the cortex as an efficient and simplified approach for achieving optogenetic expression across large cortical areas in the macaque brain.

In non-human primate (NHP) optogenetics, infecting large cortical areas with viral vectors is often a difficult and time-consuming task. Here, we ...

Cochlear Surface Preparation in the Adult Mouse

Auditory processing in the cochlea depends on the integrity of the mechanosensory hair cells. Over a lifetime, hearing loss can be acquired from numerous etiologies such as exposure to excessive noise, the use of ototoxic medications, bacterial or viral ear infections, head injuries, and the aging process. Loss of sensory hair cells is a common pathological feature of the varieties of acquired hearing loss. Additionally, the inner hair cell synapse can be damaged by mild insults. Therefore, surface preparations of cochlear epithelia, in combination with immunolabeling techniques and confocal imagery, are a very useful tool for the investigation of cochlear pathologies, including losses of ribbon synapses and sensory hair cells, changes in protein levels in hair cells and supporting cells, hair cell regeneration, and determination of report gene expression (i.e., GFP) for verification of successful transduction and identification of transduced cell types. The cochlea, a bony spiral-shaped structure in the inner ear, holds the auditory sensory end organ, the organ of Corti (OC). Sensory hair cells and surrounding supporting cells in the OC are contained in the cochlear duct and rest on the basilar membrane, organized in a tonotopic fashion with high-frequency detection occurring in the base and low-frequency in the apex. With the availability of molecular and genetic information and the ability to manipulate genes by knockout and knock-in techniques, mice have been widely used in biological research, including in hearing science. However, the adult mouse cochlea is miniscule, and the cochlear epithelium is encapsulated in a bony labyrinth, making microdissection difficult. Although dissection techniques have been developed and used in many laboratories, this modified microdissection method using cell and tissue adhesive is easier and more convenient. It can be used in all types of adult mouse cochleae following decalcification.

This article presents a modified cochlear surface preparation method that requires decalcification and use of a cell and tissue adhesive to adhere the pieces of cochlear epithelia to 10 mm round cover slips for immunohistochemistry in adult mouse cochleae.

Auditory processing in the cochlea depends on the integrity of the mechanosensory hair cells. Over a lifetime, hearing loss can be acquired from numerous ...

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta. Gait abnormalities, including decreased arm swing, slower walking speed, and shorter steps are common in PD patients and appear early in the course of disease. Thus, the quantification of motor patterns in animal models of PD will be important for phenotypic characterization during disease course and upon therapeutic treatment. Most cases of PD are idiopathic; however, the identification of hereditary forms of PD uncovered gene mutations and variants, such as loss-of-function mutations in Pink1 and Parkin, two proteins involved in mitochondrial quality control that could be harnessed to create animal models. While mice are resistant to neurodegeneration upon loss of Pink1 and Parkin (single and combined deletion), in rats, Pink1 but not Parkin deficiency leads to nigral DA neuron loss and motor impairment. Here, we report the utility of FTIR imaging to uncover gait changes in freely walking young (2 months of age) male rats with combined loss of Pink1 and Parkin prior to the development of gross visually apparent motor abnormality as these rats age (observed at 4-6 months), characterized by hindlimb dragging as previously reported in Pink1 knockout (KO) rats.

Here we describe the RatWalker system, built by redesigning the MouseWalker apparatus to accommodate for the increased size and weight of rats. This system uses frustrated total internal reflection (FTIR), high-speed video capture, and open-access analysis software to track and quantify gait parameters.

Parkinson's disease (PD) is a progressive neurodegenerative disorder caused by the loss of dopaminergic (DA) neurons in the substantia nigra pars ...

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Motor symptoms of Parkinson's disease (PD)-bradykinesia, akinesia, and tremor at rest-are consequences of the neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) and dopaminergic striatal deficit. Animal models have been widely used to simulate human pathology in the laboratory. Rodents are the most used animal models for PD due to their ease of handling and maintenance. Moreover, the anatomy and molecular, cellular, and pharmacological mechanisms of PD are similar in rodents and humans. The infusion of the neurotoxin, 6-hydroxydopamine (6-OHDA), into a medial forebrain bundle (MFB) of rats reproduces the severe destruction of dopaminergic neurons and simulates PD symptoms. This protocol demonstrates how to perform the unilateral microinjection of 6-OHDA in the MFB in a rat model of PD and shows the motor deficits induced by 6-OHDA and predicted dopaminergic lesions through the stepping test. The 6-OHDA causes significant impairment in the number of steps performed with the contralateral forelimb.

The 6-hydroxydopamine (6-OHDA) model has been used for decades to advance the understanding of Parkinson's Disease. In this protocol, we demonstrate how to perform unilateral nigrostriatal lesions in the rat by injecting 6-OHDA in the medial forebrain bundle, assess motor deficits, and predict lesions using the stepping test.

Motor symptoms of Parkinson's disease (PD)-bradykinesia, akinesia, and tremor at rest-are consequences of the neurodegeneration of dopaminergic neurons in ...

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Levodopa (L-DOPA) remains the gold-standard therapy used to treat Parkinson&#39;s disease (PD) motor symptoms. However, unwanted involuntary movements known as L-DOPA-induced dyskinesias (LIDs) develop with prolonged use of this dopamine precursor.&#160;It is estimated that the incidence of LIDs escalates to approximately 90% of individuals with PD within 10&#8211;15 years of treatment. Understanding the mechanisms of this malady and developing both novel and effective anti-dyskinesia treatments requires consistent and accurate modeling for pre-clinical testing of therapeutic interventions. A detailed method for reliable induction and comprehensive rating of LIDs following 6-OHDA-induced nigral lesioning in a rat model of PD is presented here. Dependable LID assessment in rats provides a powerful tool that can be readily utilized across laboratories to test emerging therapies focused on reducing or eliminating this common treatment-induced burden for individuals with PD.

This article describes methods to induce and evaluate levodopa-induced dyskinesias in a rat model of Parkinson&#39;s disease. The protocol offers detailed information regarding the intensity and frequency of a range of dyskinetic behaviors, both dystonic and hyperkinetic, providing a reliable tool to test treatments targeting this unmet medical need.

Levodopa (L-DOPA) remains the gold-standard therapy used to treat Parkinson&#39;s disease (PD) motor symptoms. However, unwanted involuntary movements ...